CNO Financial Group Inc. research snapshot
CNO AI stock analysis as of the August 3, 2026 data cutoff reads CNO Financial Group as a middle-market insurance holding company with improving short-term momentum. The Q2 2026 report released July 30, 2026 beat expectations: operating EPS of $1.26 rose 45% year over year, revenue reached $1.285 billion up about 35%, and management raised 2026 operating EPS guidance by 8% at the midpoint, citing strong sales and investment income. The stock responded by setting a new 52-week high of $57.59 intraday on July 31 before closing at $55.09, which is above the $51.75 consensus analyst target. The counterweights are a thin GAAP profit margin near 5.4%, a debt-to-equity ratio above 170%, the Conseco bankruptcy legacy from 2002, and a trailing P/E near 22x that prices in much of the recent improvement. The AI view is a positive watch framework with scenario ranges, not a buy or sell instruction.
Current price
$55.09
Market cap
$5.14 billion
AI score
61 / 100
Rating
Improving execution and raised operating guidance, but the stock has moved above the consensus price target and still carries high balance-sheet leverage
Trend status
Broke out to a new 52-week high of $57.59 after the July 30, 2026 Q2 beat, then closed at $55.09 on July 31, 2026, above the $51.75 analyst consensus target
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | CNO sells Medicare supplement, supplemental health, life insurance, and annuities to middle-income pre-retirees and retirees under the Bankers Life, Colonial Penn, and Washington National brands. Total new annualized premiums rose 7% in Q2 2026, the 16th consecutive quarter of insurance sales growth. | Medium |
| Moat | Brand recognition (Colonial Penn, Bankers Life), direct-to-consumer marketing, and licensed agent networks provide some insulation, and an aging U.S. demographic supports demand. Pricing power and switching costs remain limited versus larger peers such as MetLife, Prudential, Unum, and F&G Annuities & Life. | Medium-low |
| Management | CEO Gary C. Bhojwani has led the company since 2010 and oversaw the post-Conseco rebrand and balance sheet restructuring. Capital allocation focuses on debt reduction, dividends (14th consecutive annual increase in May 2026, to $0.18 per quarter), and buybacks. Q2 2026 operating ROE of 13.1% and a full-year guidance raise reflect disciplined execution. | Medium |
| Financial trend | Q2 2026 net income was $125.9 million, or $1.33 per diluted share, versus $91.8 million a year ago. Operating EPS rose 45% in the quarter and 39% year to date, and management raised 2026 operating EPS guidance by 8% at the midpoint. TTM revenue is $4.51 billion with TTM net income of $245.5 million. | Medium |
| Valuation | At $55.09 the stock trades at about 22.0x trailing earnings, 1.97x book value, and roughly 1.14x sales. The levered free cash flow yield is near 20%, but the stock is above the $51.75 consensus analyst target, and the debt-to-equity ratio above 170% raises questions about how much free cash flow can be returned to shareholders. | Medium |
| Technical trend | The stock set a new 52-week high of $57.59 intraday on July 31, 2026, after the Q2 beat, then closed at $55.09. Momentum is strongly positive with the stock up roughly 26% year to date, but the stock closed below its intraday high, leaving room for consolidation near the breakout level. | Medium |
| Risk level | Elevated by high balance-sheet leverage, thin GAAP margins, interest rate and claims experience sensitivity, regulatory exposure, dependence on investment income, and the overhang from the 2002 Conseco Chapter 11 bankruptcy that still keeps the consensus target below the current price. | Medium |
| AI confidence | Market data and Q2 2026 reported figures are well documented and cross-validated. Forward scenarios remain highly conditional on interest rates, claims experience, investment income, debt management, and whether the market multiple holds after the post-earnings run. | Medium data confidence |
| Investment certainty | The insurance businesses are understandable and cash generative, but buying at $55.09 after a strong run leaves a thin margin of safety versus the $51.75 consensus target, and the high leverage limits error tolerance. | Medium-low |
CNO AI stock forecast
The CNO AI stock forecast is a scenario framework, not a promised target. The calculation starts from consensus 2026 operating EPS near $4.44 to $4.58, a July 31, 2026 reference price of $55.09, and distinct three-year growth and multiple assumptions, producing a wide range of outcomes. A more conservative TTM EPS basis of $2.50 would produce lower absolute numbers, so treat these as directional ranges.
About $72 to $80
More likely if CNO sustains high-single-digit to low-double-digit operating EPS growth, continues to raise guidance, reduces debt leverage, keeps claims experience favorable, and the market re-rates the stock toward a 13x forward multiple as the Conseco legacy discount fades.
About $55 to $62
More likely if operating EPS compounds in the mid-single digits, guidance holds, the dividend keeps growing modestly, valuation stays near 11x forward earnings, and the stock consolidates around current levels above the $51.75 consensus target.
About $38 to $44
More likely if claims deterioration, adverse interest rate movements, investment income volatility, or recessionary pressure on the middle-income customer base compresses the forward multiple toward 9x and undercuts the elevated earnings assumptions priced in after the Q2 beat.
CNO AI technical analysis
CNO AI technical analysis uses independently available price data through the July 31, 2026 close. The stock closed at $55.09 on July 31 after setting a new 52-week high of $57.59 intraday, up about 3% on the day following the Q2 earnings beat. These levels are a price-action framework based on the data cutoff, not a live chart feed, and should be refreshed before any trading decision.
| Level | Value | Why it matters |
|---|---|---|
| Current price reference | $55.09 close on July 31, 2026; intraday high $57.59 | StockAnalysis.com real-time quote, last checked August 3, 2026. |
| 52-week range | $35.24 to $57.59 | The upper bound is a new high set July 31, 2026, extending the strong recovery from 2025 lows. |
| Immediate support | $53.00 to $54.00 | The July 30 close near $53.49 and the round-number zone that held during the breakout. |
| Lower support | $50 to $52 | The area around the $51.75 consensus target and psychological $50 level; a pullback here would be the first test of the breakout. |
| Near resistance | $57.59 then about $60 | The July 31 intraday high is the immediate ceiling. A clean close above $57.59 on volume would open the round-number $60 zone. |
| 50-day moving average | Estimated near $48 to $52 | Estimated from available price history given the late-July acceleration; use a current chart before relying on this indicator. |
| 200-day moving average | Not independently verified | Use a current chart before relying on this long-term trend signal. |
| Momentum | Strongly positive | The stock is up roughly 26% year to date and about 56% above the 52-week low of $35.24, with the breakout driven by the Q2 earnings beat. |
| Volume | About 1.39 million shares on July 31, 2026 | Well above the average of roughly 806,000 shares, confirming participation in the breakout day. |
| Volatility marker | $35.24 to $57.59 over 52 weeks | A wide range reflecting both business recovery and general market conditions. |
| Invalidation | Sustained close below $50 | A break back below the $50 to $52 support zone would weaken the post-earnings breakout and suggest the rally ran ahead of the fundamentals. |
CNO AI trading strategy
The CNO AI trading strategy is a rules-based research framework, not personal advice. It pairs insurance-sector and cash-flow evidence with observable price levels and predefined invalidation conditions, using the data cutoff of August 3, 2026.
Watch for a sustained close above $57.59 (the July 31, 2026 intraday high) on above-average volume. Confirm with evidence that operating EPS growth, sales momentum, and the raised 2026 guidance continue in the next quarterly report.
Treat a reversal below $53 or a failed breakout that falls back under the July 30 close as a rules-based signal to reduce exposure.
If CNO pulls back toward the $50 to $52 zone, compare the price action with quarterly operating EPS, net investment income stability, claims experience, and leverage ratios before assuming the breakout support will hold.
Do not average down solely because the stock fell. Size risk for further downside given the elevated debt and the stock trading above the consensus target.
Track quarterly operating EPS versus raised guidance, revenue growth by segment, operating ROE, book value per share, debt-to-equity, dividend coverage, and buyback execution, plus any commentary on interest rates and claims experience on the earnings call.
Reassess the thesis if operating margins compress, debt ratios increase, guidance is cut, investment income weakens, or the macroeconomic outlook for the middle-income insurance customer deteriorates.
Investment research summary
CNO Financial Group sells Medicare supplement, supplemental health, life insurance, and annuity products to middle-income pre-retiree and retired Americans. Customers pay for financial protection, Medicare supplement coverage, and guaranteed income products distributed through Bankers Life agents, Colonial Penn direct marketing, and Washington National supplemental channels, with health products the largest segment and total new annualized premiums up 7% in Q2 2026.
Its moat rests on established brand names (Colonial Penn, Bankers Life), direct-to-consumer reach, licensed agent networks, and an aging U.S. population driving Medicare supplement and senior insurance demand. It is not wide: larger competitors like MetLife, Prudential, Unum, and F&G Annuities & Life have greater scale, lower cost of capital, and more diversified product lines, and CNO cannot raise prices freely without losing middle-income customers.
The thesis can fail if claims experience deteriorates, net investment income falls or turns volatile, the middle-income customer base comes under economic pressure, debt service constraints limit capital return flexibility, or the Conseco bankruptcy legacy keeps the market from assigning a higher multiple. The Q2 beat raised expectations, so a miss against the new, higher guidance would hit the stock harder.
Gary C. Bhojwani has been CEO since 2010, overseeing the corporate rebranding and balance sheet restructuring. The key management tests are disciplined capital allocation between debt reduction, dividends (raised for the 14th consecutive year in May 2026 to $0.18 per quarter), and buybacks; maintaining stable underwriting margins; and proving that the 45% operating EPS growth and raised 2026 guidance are repeatable rather than a one-quarter benefit from investment income.
The insurance industry benefits from an aging U.S. population, rising healthcare costs that support Medicare supplement demand, and growing awareness of retirement income needs. Challenges include regulatory changes, interest rate sensitivity, competitive pressure from larger and more diversified insurers, and the vulnerability of the middle-income target demographic to economic cycles.
At $55.09 the stock trades at about 22.0x trailing earnings, 1.97x book value, and roughly 1.14x sales, with a levered free cash flow yield near 20%. The consensus analyst target of $51.75 is below the current price, and a forward P/E near 12x still depends on the raised operating EPS estimates holding. A margin of safety depends on demonstrated debt reduction, margin improvement, and organic growth, not on assuming the post-earnings multiple will expand further.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CNO stock price | $55.09 close on July 31, 2026, after a $57.59 intraday high | StockAnalysis.com real-time quote | August 3, 2026 |
| Market cap | $5.14 billion, computed as $55.09 x 93.35 million shares | StockAnalysis.com; financial_rigor.py verification (0.05% deviation) | August 3, 2026 |
| 52-week range | $35.24 to $57.59 | StockAnalysis.com; Yahoo Finance | August 3, 2026 |
| Q2 2026 net income | $125.9 million, or $1.33 per diluted share, versus $91.8 million a year ago | CNO Financial Group Q2 2026 earnings release | July 30, 2026 |
| Q2 2026 operating EPS | $1.26 per diluted share, up 45% year over year; operating ROE 13.1% | CNO Financial Group Q2 2026 earnings release | July 30, 2026 |
| Q2 2026 revenue | $1.285 billion, up about 34.6% year over year, beating consensus near $993 million | StockAnalysis.com; StockStory; Zacks | August 3, 2026 |
| 2026 operating EPS guidance | Raised by 8% at the midpoint | CNO Financial Group Q2 2026 earnings release | July 30, 2026 |
| Book value per share | $27.96; $39.92 excluding accumulated other comprehensive loss, up 5% | CNO Financial Group Q2 2026 earnings release | July 30, 2026 |
| EPS (TTM) | $2.50 | Yahoo Finance; StockAnalysis.com | August 3, 2026 |
| Revenue (TTM) | $4.51 billion | Yahoo Finance | August 3, 2026 |
| Net income (TTM) | $245.5 million | Yahoo Finance; StockAnalysis.com | August 3, 2026 |
| Profit margin | 5.44% | Yahoo Finance | August 3, 2026 |
| Price / Book (mrq) | 1.98x (Yahoo Finance); 1.97x computed at $55.09 / $27.96 | Yahoo Finance; financial_rigor.py verification | August 3, 2026 |
| ROE (TTM) | 9.76% | Yahoo Finance | August 3, 2026 |
| Total cash (mrq) | $1.41 billion | Yahoo Finance | August 3, 2026 |
| Debt / Equity (mrq) | 172.19% | Yahoo Finance | August 3, 2026 |
| Levered free cash flow (TTM) | $1.03 billion | Yahoo Finance | August 3, 2026 |
| Forward dividend and yield | $0.72 per share, about 1.31% yield at $55.09 | StockAnalysis.com; Yahoo Finance | August 3, 2026 |
| Beta (5Y monthly) | 0.82 | Yahoo Finance; StockAnalysis.com | August 3, 2026 |
| Analyst consensus and target | Hold rating; $51.75 average target with a range of $47 to $55 | Yahoo Finance; StockAnalysis.com forecast | August 3, 2026 |
| Share count and market-cap check | 93.35 million shares; $55.09 x 93.35M = $5.14B | StockAnalysis.com; financial_rigor.py calculation | August 3, 2026 |
This CNO AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios use available public data as of the August 3, 2026 data cutoff and can be wrong if earnings, claims experience, interest rates, investment income, valuation multiples, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
